Pharmaceutical company Roche is entering the fight against obesity with the $2.7 billion (CHF2.3 billion) takeover of United States firm Carmot Therapeutics.
Milestone payments of up to $400 million can also be made. According to Monday's announcement, Carmot Therapeutics is privately held and has in its pipeline product candidates that can be used to treat obesity in patients with and without diabetes. They are all based on the novel GLP-1 mechanism of action, which has recently been the subject of a lot of media attention.
Recently, the drug Wegovy caused a stir. It is a product from the Danish pharmaceutical company Novo Nordisk. It contains the active ingredient semaglutide, which promotes weight loss in people who are very overweight. ...